|
US2011021425A1
|
|
Tricyclic inhibitors of JAK
|
|
WO2010129564A1
|
|
Systems and methods for tailoring acute and chronic viral infection treatments to increase the probability of "cure" for a given subject
|
|
US2009218708A1
|
|
Process for preparing concentrated aqueous micellar solutions
|
|
US2009306041A1
|
|
Inhibitors of Bruton's tyrosine kinase
|
|
US2009197931A1
|
|
Imidazolinylmethyl aryl sulfonamide
|
|
US2010173281A1
|
|
HCV NS3 protease replicon shuttle vectors
|
|
US2009143288A1
|
|
Peptide-complement conjugates
|
|
US2007141554A1
|
|
Stable cell lines expressing hERG
|
|
US2006154914A1
|
|
Dibenzoxazepinone derivatives and uses thereof
|
|
US2006069094A1
|
|
Compositions and methods for treating cognitive disorders
|
|
US2006106012A1
|
|
Benzoxazine and quinoxaline derivatives and uses thereof
|
|
CN102114244A
|
|
Compositions and methods for treating cognitive disorders
|
|
CN101115769A
|
|
Interferon-alpha polypeptides and conjugates
|
|
US2005239880A1
|
|
Methods for treating retroviral infections
|
|
US2005239881A1
|
|
Non-nucleoside reverse transcriptase inhibitors
|
|
US2006051780A1
|
|
Polymorphic Plasminogen genes and uses thereof
|
|
US2005143375A1
|
|
Imidazole derivatives
|
|
CN1882585A
|
|
Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
|
|
CN1863812A
|
|
Polymorphic antiviral nucleoside compounds
|
|
CN1835931A
|
|
Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CFR antagonists
|
